Vaishali Pharma Limited (VAISHALI.NS)
- Previous Close
12.05 - Open
11.90 - Bid --
- Ask --
- Day's Range
10.90 - 12.05 - 52 Week Range
10.30 - 24.91 - Volume
1,566,307 - Avg. Volume
691,802 - Market Cap (intraday)
1.487B - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
190.00 - EPS (TTM)
0.06 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, cardiac, anti-diabetic, anti-inflamatory/ananlgesic/anti-pyretic, topical steroids/corticosteroids, anti-fungal, vitamins, and other formulations. In addition, it offers veterinary, nutraceutical, oncology, herbal, and surgical products. The company was formerly known as Vaishali Pharma Private Limited. Vaishali Pharma Limited was founded in 1989 and is based in Mumbai, India.
www.vaishalipharma.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: VAISHALI.NS
View MorePerformance Overview: VAISHALI.NS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VAISHALI.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VAISHALI.NS
View MoreValuation Measures
Market Cap
1.49B
Enterprise Value
1.33B
Trailing P/E
200.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.38
Price/Book (mrq)
2.19
Enterprise Value/Revenue
1.40
Enterprise Value/EBITDA
33.33
Financial Highlights
Profitability and Income Statement
Profit Margin
0.43%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
991.76M
Net Income Avi to Common (ttm)
4.27M
Diluted EPS (ttm)
0.06
Balance Sheet and Cash Flow
Total Cash (mrq)
11.43M
Total Debt/Equity (mrq)
19.36%
Levered Free Cash Flow (ttm)
--